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Abstract: The mechanisms by which microRNAs control pediatric high-grade gliomas (pHGGs) have
yet to be fully elucidated. Our studies of patient-derived pHGG tissues and of the pHGG cell line
KNS42 revealed down-regulation in these tumors of three microRNAs, specifically miR-107, miR-181c,
and miR-29a-3p. This down-regulation increases the proliferation of KNS42 cells by de-repressing
expression of the Notch2 receptor (Notch2), a validated target of miR-107 and miR-181c and a
putative target of miR-29a-3p. Inhibition (either pharmacologic or genetic) of Notch2 or re-expression
of the implicated microRNAs (all three combined but also individually) significantly reduced KNS42
cell proliferation. These findings suggest that Notch2 pathway activation plays a critical role in
pHGGs growth and reveal a direct epigenetic mechanism that controls Notch2 expression, which
could potentially be targeted by novel forms of therapy for these childhood tumors characterized by
high-morbidity and high-mortality.
Keywords: pediatric high-grade gliomas; Notch2 signaling; microRNAs; miR-107; miR-181c;
miR-29a-3p; cell proliferation
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1. Introduction
Gliomas represent the most common brain tumors in children. Approximately 21% of all
primary pediatric gliomas are high-grade tumors [1,2]. These tumors are histologically similar
to adult high-grade gliomas (aHGGs), but their genetic and epigenetic features reflect intrinsic
differences with respect to their adult counterparts. Recent genome and epigenome profiling of
pediatric high-grade gliomas (pHGGs) has markedly expanded our knowledge of their biology.
Nevertheless, the therapeutic options for these tumors are still very limited, and the long-term outlook
for patients is unfavorable, with high levels of both morbidity and mortality [3,4]. Identifying the
molecular pathways that drive pHGGs is essential for the development of new, more effective treatment
strategies [4,5].
The Notch signaling pathway regulates a number of cellular processes, such as gliogenesis,
self-renewal, and cell-fate specification [6–8]. The Notch genes encode four transmembrane receptors
(Notch1–4), which are activated by their interaction with ligands of the Serrate/Jagged and Delta
families. Ligand binding induces proteolytic cleavages of the receptor, which ultimately result in
the release of the intracellular domain and its migration into the nucleus, where it activates the
transcription of Notch target genes [9–11]. Deregulation of the Notch pathway has been described in
a variety of cancers [5,12–16], including aHGGs [12,17,18], but little is known about the relevance of
Notch signaling in pHGGs. Immunohistochemical studies of patient-derived tumor tissues indicate
that active Notch signaling is a feature of pHGGs, including those that are negative for Notch1 receptor
(Notch1) [19]. This observation raises the possibility that other Notch receptors may be playing
important functional roles in these tumors. Thus far, however, this issue has yet to be explored.
In the present study, we analyzed Notch2 receptor (Notch2) expression in tissue samples of
pHGGs and found it to be increased with respect to that found in normal brain tissue. Pharmacological
or genetic suppression of Notch2 signaling in the human pHGG cell line, KNS42, significantly reduced
pHGG cell proliferation rates. In light of the growing body of evidence pointing to microRNAs as major
mediators of deregulated gene expression in tumors [20], including pHGGs [5], we hypothesized that
the activation of Notch2 signaling in pHGGs might be related at least in part to under-expression of one
or more microRNAs. Here we show that three microRNAs previously reported to be down-regulated
in pHGGs [5] were found to target the 3′-UTR of Notch2: miR-107, miR-181c and miR-29a-3p, and
their re-expression in KNS42 cells produced substantial reductions in Notch2 protein levels and cell
proliferation rates. These findings reveal a novel network that controls pHGG cell growth and identify
new molecular targets for more effective treatment of these devastating pediatric brain tumors.
2. Results
2.1. Notch1 and Notch2 Receptor Expression in pHGG Tumors
We assessed nuclear expression levels of the Notch1 and Notch2 in tissue sections from pHGGs.
Sections of normal brain tissue were used as reference control (CTRL). As expected, based on data
reported by Fouladi et al., the pHGG tissues displayed weak or any nuclear positivity for the activated
form of Notch1 (NICD1), which was comparable to that of the control tissue (Figure 1A,C). In contrast,
nuclear positivity for Notch2 in the tumor tissues was markedly stronger than that seen in the
non-neoplastic brain tissue (Figure 1B,D). These findings indicate that pHGGs are characterized by
increased levels of activated Notch2 (NICD2), supporting our hypothesis that this Notch receptor plays
a functional role in these tumors. They might also explain the Notch signaling activation observed in
pHGGs in which Notch1 expression was low or absent [19].
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Figure 1. Notch1 and Notch2 expression in pHGG and non-neoplastic brain tissues. Representative 
images of immunohistochemical (IHC) staining of NICD1 (A) and Notch2 (B) and relative IHC 
scores (C,D) for nuclear expression of NICD1 and Notch2 in 10 pHGGs and normal brain tissue. 
* p < 0.05 vs. control (CTRL). Scale bars in (A,B): 100 μm. 
2.2. Notch2 Inhibition Reduces pHGG Cell Proliferation 
We next investigated the biological role of Notch2 in pHGGs by using the pHGG cell line 
KNS42 [21]. As shown in Figure 2A, immunofluorescence analysis showed that these cells—like the 
patient-derived pHGG tissues examined by IHC—contained high nuclear levels of Notch2.  
In particular, by counting the number of positive cells nuclei, we obtained that about the 90% of 
KNS42 expressed Notch2 in the cell nuclei. This finding was confirmed both by Western blot 
analysis performed with a specific antibody for NICD2 (Figure 2B) and by performing a 
nuclear/cytoplasm fractionation assay that demonstrates that NICD2 is only expressed in cell nuclei 
(Figure S1). 
The KNS42 cells were then treated for 96 h with the gamma-secretase inhibitor (GSI), 
N-(N-(3,5-difluorophenacetyl)-L-alanyl)-2-phenylglycine t-Butyl ester [22], which blocks the activity 
of all four Notch receptors. Western blot studies revealed dose-dependent reduction of NICD2 levels 
in treated cells (Figure 2C) and this effect was associated with a decline in cell proliferation, which 
became significant after treatment with GSI both at 5 and 10 μM (Figure 2D). This anti-proliferative 
effect was due to apoptosis, as demonstrated by the significant increase in the cleaved form of PARP 
shown in Supplementary Figure S2. To investigate the contribution of Notch2 inhibition to the 
effects produced by the GSI, we transfected KNS42 cells with a siRNA that specifically targeted 
Notch2 (siNotch2). We observed appreciably lower levels of NICD2 in transfected cells (Figure 2E) 
without any reduction of Notch1 expression level, as reported in Supplementary Figure S3, 
underlying that siNotch2 was specific to Notch2 only. The lower levels of NICD2 were associated 
with significant decreases in cell proliferation, which were already evident 72 h after siNotch2 
silencing (Figure 2F). Collectively, these results confirm our hypothesis that Notch2 plays a 
substantial role in the Notch-mediated control of pHGG cell proliferation. 
Figure 1. Notch1 and Notch2 expression in pHGG and non-neoplastic brain tissues. Representative
images of immunohistochemical (IHC) staining of NICD1 (A) and Notch2 (B) and relative IHC scores
(C,D) for nuclear expression of NICD1 and Notch2 in 10 pHGGs and normal brain tissue. * p < 0.05 vs.
control (CTRL). Scale bars in (A,B): 100 µm.
2.2. Notch2 Inhibition Reduces pHGG Cell Proliferation
We next investigated the biological role of Notch2 in pHGGs by using the pHGG cell line
KNS42 [21]. As shown in Figure 2A, immunofluorescence analysis showed that these cells—like
the patient-derived pHGG tissues examined by IHC—contained high nuclear levels of Notch2.
In particular, by counting the number of positive cells nuclei, we obtained that about the 90% of
KNS42 expressed Notch2 in the cell nuclei. This finding was confirmed both by Western blot analysis
performed with a specific antibody for NICD2 (Figure 2B) and by performing a nuclear/cytoplasm
fractionation assay that demonstrates that NICD2 is only expressed in cell nuclei (Figure S1).
The KNS42 cells were then treated for 96 h with the gamma-secretase inhibitor (GSI),
N-(N-(3,5-difluorophenacetyl)-L-alanyl)-2-phenylglycine t-Butyl ester [22], which blocks the activity of
all four Notch receptors. Western blot studies revealed dose-dependent reduction of NICD2 levels in
treated cells (Figure 2C) and this effect was associated with a decline in cell proliferation, which became
significant after treatment with GSI both at 5 and 10 µM (Figure 2D). This anti-proliferative effect was
due to apoptosis, as demonstrated by the significant increase in the cleaved form of PARP shown in
Supplementary Figure S2. To investigate the contribution of Notch2 inhibition to the effects produced
by the GSI, we transfected KNS42 cells with a siRNA that specifically targeted Notch2 (siNotch2).
We observed appreciably lower levels of NICD2 in transfected cells (Figure 2E) without any reduction
of Notch1 expression level, as reported in Supplementary Figure S3, underlying that siNotch2 was
specific to Notch2 only. The lower levels of NICD2 were associated with significant decreases in cell
proliferation, which were already evident 72 h after siNotch2 silencing (Figure 2F). Collectively, these
results confirm our hypothesis that Notch2 plays a substantial role in the Notch-mediated control of
pHGG cell proliferation.




Figure 2. Notch2 expression in KNS42 cells and the impact of its inhibition on proliferation.
(A) Immunofluorescence labeling of Notch2 expression in KNS42 cells counterstained with the
nuclear marker Hoechst. (BF, bright field.) Scale bars: 20 µm; (B) Western blot analysis of the
trans-membrane form of Notch2 (Notch2 NTM) and NICD2 levels in KNS42 cells and SC-011 cells
(used as positive controls); (C,D) dose-dependent effects of 96 h exposure to GSI on (C) NICD2 levels
and (D) proliferation in KNS42 cells; (E,F) Effects of siRNA-mediated knockdown of Notch2 in KNS42
cells; (E) Western blot analysis of NICD2 levels 96 h after transfection. (F) Time-course of the effects of
Notch2 silencing on KNS42 cell proliferation. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. CTRL (untreated
cells in panel C and D, silencing negative control-transfected cells in panel E and F).
2.3. Notch2 High Levels Are Maintained by Low Levels of miR-107, miR-181c and miR-29a-3p
Deregulated microRNA expression has been implicated in the cancer-related overexpression of
numerous oncogenes, and our group has already shown that multiple microRNAs are differentially
expressed in pHGGs [5]. To investigate the mechanism underlying the increased Notch2 expression
in pHGG cells, we therefore examined the list of microRNAs that had displayed down-regulated
expression in pHGGs (vs. normal brain tissue) in our previous study [5]. Interrogation of miRTarBase
and microRNA.org revealed Notch2 to be a validated target of two of the microRNAs on this list
(miR-107 and miR-181c) ([23–25] and (http://mirtarbase.mbc.nctu.edu.tw) a putative target of a third,
miR-29a-3p (microRNA.org)).
Consistent with our previous findings in pHGGs [5], all three of these microRNAs were
expressed at significantly lower levels in KNS42 cells than in non-neoplastic brain tissues (CTRL)
(Figure 3A). To analyze the biological impact of this down-regulation, we then overexpressed the
microRNAs, individually and combined, in KNS42 cells. After verifying the physiological range
of their re-expression levels by RT-qPCR (Figure 3B), we assessed the ability of the microRNAs to
diminish NICD2 protein levels. As shown in Figure 3C, both overexpression of each microRNA and of
their combination significantly decreased the levels of NICD2. Based on the findings shown in Figure 2,
we expected that overexpression of these microRNAs would also be associated with reduced pHGG cell
proliferation. Trypan blue exclusion assays showed that KNS42 cell death was not significantly affected
by overexpression of any of the microRNAs, even when combined (Data not shown). In contrast,
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as shown in Figure 3D, by post-transfection hour 72, proliferation was already significantly decreased
in cells overexpressing all three microRNAs or miR-181c alone. By 96 h, these reductions were even
more evident, and the effect was also statistically significant for cells overexpressing miR-107 or
miR-29a-3p alone. Importantly, at both time points, the anti-proliferative effect was more substantial
in cells subjected to combined overexpression of the three microRNAs, indicating that miR-29a-3p,
miR-107, and miR-181c may act synergically to check KNS42 cell proliferation. We analyzed the
role of these three microRNAs in other two immortalized cell lines derived from different glioma
grades. Specifically, we used two pediatric low-grade glioma cell lines: Res259, derived from a grade
II diffuse astrocytoma, and Res186, derived from a grade I pilocytic astrocytoma. Firstly, we evaluated
the level of expression of miR-29a-3p, miR-107, and miR-181c in Res259 and Res186. As shown in
Supplementary Figure S4A, we found that their level of expression was comparable to the one we
found in KNS42 cells. Then, as reported in Supplementary Figure S4B and S4C, we also demonstrated
the ability of these microRNAs in reducing cell proliferation after their re-expression in both pediatric
low-grade glioma cell lines. Specifically, Res259 cells seem to be more sensitive than Res186. Cell
proliferation indeed was significantly affected by the overexpression of all microRNAs in Res259;
while in Res186 only miR-29a-3p and the combined overexpression of the three microRNAs induced a
significant effect. The anti-proliferative action of these microRNAs in Res259 and Res186 cells did not
increase after 96h in respect to what we observed at 48h (Data not shown).
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Figure 3. miR-107, miR-181c and miR-29a-3p inhibit pHGG cell proliferation by targeting Notch2. 
(A) Single assay qPCR validation of miR-107, miR-181c, and miR-29a-3p expression in KNS42 cells 
versus non-neoplastic total brain (CTRL). * p < 0.05 vs. CTRL; (B,C) KNS42 cells were transfected 
with 20 nM of miR-107, miR-181c, or miR-29a-3p: pre-transfection (CTRL) and 48 h-post-transfection 
(O/E) levels of (B) each microRNA and (C) of the trans-membrane form of Notch2 (Notch2 NTM) 
and of NICD2. * p < 0.05 vs. CTRL; (D) KNS42 cell proliferation after O/E of the three microRNAs, 
separately and combined. Significant differences vs. CTRL at 72 h (*p < 0.05, ** p < 0.01) and at 96 h (° 
p < 0.05, °° p < 0.01, °°°° p < 0.0001); (E) Renilla activity induced by ectopic expression of Notch2 and 
negative control (CTRL) in KNS42 cells transfected with Renilla vector bearing the Notch2 3′UTR. 
miR-107, whose targeting of Notch2 has been previously validated, was used as positive control. 
Results are expressed as the ratio of Renilla to Firefly luciferase activity. ** p < 0.01 vs. 3′UTR/CTRL. 
Figure 3. miR-107, miR-181c and miR-29a-3p inhibit pHGG cell proliferation by targeting Notch2.
(A) Single assay qPCR validation of miR-107, miR-181c, and miR-29a-3p expression in KNS42 cells
versus non-neoplastic total brain (CTRL). * p < 0.05 vs. CTRL; (B,C) KNS42 cells were transfected with
20 nM of miR-107, miR-181c, or miR-29a-3p: pre-transfection (CTRL) and 48 h-post-transfection (O/E)
levels of (B) each microRNA and (C) of the trans-membrane form of Notch2 (Notch2 NTM) and of
NICD2. * p < 0.05 vs. CTRL; (D) KNS42 cell proliferation after O/E of the three microRNAs, separately
and combined. Significant differences vs. CTRL at 72 h (*p < 0.05, ** p < 0.01) and at 96 h (◦ p < 0.05,
◦◦ p < 0.01, ◦◦◦◦ p < 0.0001); (E) Renilla activity induced by ectopic expression of Notch2 and negative
control (CTRL) in KNS42 cells transfected with Renilla vector bearing the Notch2 3′UTR. miR-107,
whose targeting of Notch2 has been previously validated, was used as positive control. Results are
expressed as the ratio of Renilla to Firefly luciferase activity. ** p < 0.01 vs. 3′UTR/CTRL.
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As noted above, unlike that of miR-107 and miR-181c [23–25], the binding of miR-29a-3p to the
3′-UTR of Notch2 has been never experimentally validated. To address this gap, we cloned a portion
of the Notch2 3′UTR containing the putative binding site for miR-29a-3p into a luciferase reporter
vector and transfected it into KNS42 cells. As shown in Figure 3E, re-expression of miR-29a-3p in
these cells significantly reduced expression of the reporter gene in the recombinant vector containing
the 3′-UTR of Notch2, thereby providing the first experimental evidence that miR-29a-3p is a direct
negative regulator of Notch2 expression.
Taken together, these observations confirm that the high levels of Notch2 of pHGG cells
are maintained at least in part through the down-regulated expression of miR-107, miR-181c,
and miR-29a-3p.
3. Discussion
MicroRNAs are critical components of the post-transcriptional machinery that regulates tumor
cell growth [26,27]. In the present study we identified a microRNA-based mechanism that
activates proliferative Notch2 signaling in pHGGs. In particular, our data show that: (1) pHGGs
frequently express high levels of NICD2 and little or no Notch1; (2) pharmacological inhibition or
siRNA-mediated knockdown of Notch2 in KNS42 pHGG cells significantly reduces their proliferation
rates; (3) the hyper-activation of Notch2 signaling in pHGG cells is maintained at least in part
by the down-regulated expression of three Notch2-targeting microRNAs—miR-107, miR-181c, and
miR-29a-3p—in KNS42 cells.
To the best of our knowledge, to date, only two studies have investigated the roles of Notch
signaling in pHGGs. In 2011, Fouladi et al. reported that FFPE sections of grade III and IV malignant
gliomas removed from pediatric patients displayed intense nuclear staining for two transcription
factors that are downstream effectors of the Notch pathway, HES1 and HES5, and this positivity
was also observed in those tumors that were immunonegative for the Notch1 [19]. More recently,
Dantas-Barbosa et al. (2015) showed that pediatric glioma xenografts and the pediatric glioma cell
line, SF188, express Notch1, the Notch ligand (DLL1), and several of the Notch pathway’s downstream
target genes (HES1, HEY1, MYC and FBXW7), but neither pharmacological nor genetic blockade of
Notch1 was capable of reducing pHGG cell growth. Nevertheless, MYC resulted to be overexpressed in
these pediatric glioma xenografts [28]. Therefore, even though the literature studies are not numerous,
both of them report evidence that Notch pathway is active in pHGGs.
The Notch signaling pathway is a highly conserved pathway that plays major roles in many
cellular processes. Its function is strongly cell context-dependent [9,29]. Notch signaling can play
oncogenic as well as oncosuppressive roles in tumorigenesis, and the four Notch receptors are also
characterized by functional diversity, even within the same biological setting [30,31].
The present work is the first attempt to delineate the specific role of Notch2 in pHGGs.
The increased nuclear levels of NICD2—the active form of the protein—that we documented in
pHGGs (patient-derived tissues as well as the KNS42 cell line) support a role for Notch2 signaling
in these tumors. This hypothesis is further supported by the results of our experiments with GSI
and siNotch2 in KNS42 cells, which showed that the increased activation of Notch2 in pHGG cells
enhances their proliferation. An oncogenic role for Notch2 in HGGs had previously been reported
only in adult tumors [18,32,33].
Our findings also reveal that the Notch2 activation documented in pHGG cells is determined
epigenetically, more specifically, by the down-regulated expression of three microRNAs. Two of these
(miR-107 and miR-181c) had already been shown to target the Notch2 3’UTR [23,24]. We used a
luciferase reporter assay to validate the binding to this region of the third, miR-29a-3p. We investigated
the effect of the down-regulation of these microRNAs only on Notch2 however, of note, other genes
such as Bcl2, Cdc42, CDK6, CRKL, HMGA2, KLF4, PLAG1, VEGFA, are validated target for two and
putative for one of the microRNAs. Therefore, we cannot exclude that they may affect cell proliferation
in the pHGG context. Interestingly, all the three microRNAs have been reported to control proliferation
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in malignant gliomas in adults [34–37], but few studies have analyzed microRNA expression in pHGGs.
Li et al. [38] found that miR-107 and miR-181c were down-regulated in both high- and low-grade
pediatric gliomas. Jha et al. [39] compared microRNA expression levels in pHGGs with those found
in brain tissue samples from patients operated for epilepsy. The tumor tissues were characterized by
down-regulation of the miR-379/656 cluster members. Up-regulated expression of several microRNAs
was also observed, including those belonging to the miR-17/92 cluster, which is consistent with our
previous findings [5]. Eguía-Aguilar et al. [40] have reported decreased expression of miR-124-3p,
miR-128-1 and miR-221-3p in astrocytomas of all grades relative to levels found in normal brain tissues.
More recently, Liang et al. [41] reported the down-regulation of miR-137 and miR-6500-3p in three
pediatric glioma cell lines, including two that were derived from high-grade tumors.
In summary, our results document a link between aberrant oncogenic pathway activation
mediated by Notch2 and the down-regulated expression of miR-107, miR-181c, and miR-29a-3p
and suggest that this network is a key regulator of pHGG cell growth. These findings have potential
implications for new targeted therapies for these tumors since the inhibition of abnormal activated
pathways could be an effective therapy to overcome the high levels of morbidity and mortality
underlying poor long-term outcomes.
4. Materials and Methods
Unless otherwise stated, commercially available products were used according to the manufacturer’s
instructions/protocols.
4.1. Ethics Statement
The study was conducted in accordance with the 1964 Declaration of Helsinki and its later
amendments or comparable ethical standards and with the guidelines of the ethical policies of the
involved institutions.
4.2. Histology
Formalin-fixed paraffin-embedded (FFPE) samples of 10 pHGGs were obtained from the
Pathology Department of the Catholic University of the Sacred Heart and from Sapienza University in
Rome. Three-micron-thick sections were stained with hematoxylin and eosin (H and E) for histology.
Tumor diagnoses were confirmed by consensus of three neuropathologists (Felice Giangaspero, Manila
Antonelli and Marco Gessi) based on World Health Organization (WHO) criteria [42].
4.3. Notch1 and Notch2 Immunohistochemistry
Immunohistochemical studies were performed using anti-activated Notch1 (#ab8925, Abcam,
Cambridge, UK) and anti-Notch2 antibody (#HPA048743, Atlas Antibodies, Sigma Aldrich, Saint Louis,
MI, USA). Paraffin-embedded slices of adult normal brain tissue purchased from the Biochain Institute
(Newark, CA, USA) and of four no autopsy derived healthy brain tissues obtained from the Pathology
Department of the Catholic University of the Sacred Heart and from Sapienza University in Rome were
used as controls. The percentage of positive nuclei in each tumor sample and in the glial population of
healthy brain tissues was calculated and results were scored as follows: 0 = nuclear positivity rate:
0–10%; 1 = nuclear positivity rate: 11–25%; 2 = nuclear positivity rate: 26–50%; 3 = nuclear positivity
rate: 51–75%; 4 = nuclear positivity rate: 76–100% [43].
4.4. Cell Lines and Treatments
Functional studies were performed with KNS42 cells purchased from the Japanese Collection
of Research Bioresources Cell Bank. Pediatric low-grade glioma cell lines Res259 and Res186 were
kindly provided by Prof. Chris Jones from the Institute of Cancer Research in London. KNS42, Res259
and Res186 cells were grown in DMEM/F12 medium and squamous cell carcinoma (SC-011) were
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grown in RPMI 1640 medium. All media were supplemented with 10% fetal bovine serum (FBS, Sigma
Aldrich, Saint Louis, MI, USA), 2 mM L-glutamine (Gln, Sigma Aldrich, Saint Louis, MI, USA) and
100 units·mL−1 antibiotic solution (100 units·mL−1 penicillin and 10000 µg·mL−1 streptomycin). Cells
were cultured at 37 ◦C in a humidified 5% CO2 atmosphere.
To assess the effects of the treatments described below, KNS42 cells were seeded into 6-well
plates (2.5 × 105 cells/well), harvested at the indicated post-treatment time points (24, 48, 72, 96 h),
and subjected to the Trypan Blue exclusion assay, by counting the number of cells that did not
take up Trypan Blue, to evaluate cell growth. Res259 and Res186 were seeded into 6-well plates
(1.8 × 105 cells/well), harvested after 96 h and subjected to the Trypan Blue exclusion assay.
Pharmacological inhibition of Notch2—KNS42 cells were incubated with GSI (Calbiochem, Merck
KGaA, Darmstadt, Germany) at concentrations of 2.5, 5.0 and 10.0 µM and CTRL (0.1% DMSO),
harvested after 96 h of exposure, and assayed.
Silencing of Notch2—For the silencing of Notch2 four individual ON-TARGET PLUS siRNA
(LQ-012235-00, Dharmacon, Lafayette, CO, USA) were transfected at 100 nM each, or by using
the ON-TARGET PLUS SMART pool (code: L-012235-00, Dharmacon, Lafayette, CO, USA).
The ON-TARGET PLUS SMART pool yielded the best knockdown efficiency, therefore it was used
for experiments, at the concentration of 100 nM. Silencing negative control was performed using
ON-TARGETplus Non-targeting Control Pool (cat. #D-001810-10, Dharmacon, Lafayette, CO, USA).
All siRNA were transfected using HiPerFect (Qiagen Inc., Milano, Italy). Proliferation was assayed
96 h after transfection.
MicroRNA overexpression—For single-microRNA overexpression, cells were transfected with
20 nM of one of the following synthetic microRNAs: miR-107 (miRIDIAN microRNA code:
C-300527-03, Dharmacon, Lafayette, CO, USA); miR-181c (miRIDIAN microRNA code: C-300556-03,
Dharmacon, Lafayette, CO, USA); miR-29a-3p (mirVana miRNA mimic code: MC12499, Ambion-Life
Technology, Thermo Scientific, Wilmington, MA, USA); or with negative control (miRIDIAN microRNA
negative control code: CN-001000-01-05, Dharmacon, Lafayette, CO, USA). For triple microRNA
overexpression treatments, we used miR-107, miR-181c and miR-29a-3p at equal concentrations to
obtain a final concentration of 20 nM. All transfections were performed with HiPerFect transfection
reagent (Qiagen Inc., Milano, Italy). Cells were assayed 48 h after transfection.
4.5. RNA Isolation and qRT-PCR
The isolation of total RNA from fresh-frozen pHGG tissue samples and KNS42 cells have been
previously described [44]. For microRNA analysis, single assay qPCR for assessment of miR-107
(code: 002112), miR-181c (code: 000443) and miR-29a-3p (code: 000482) were performed using TaqMan
Individual microRNA assays (Applied Biosystems, Waltham, MA, USA), as previously described [5].
MicroRNA expression levels were normalized to U6 small nuclear RNA (Thermo Scientific).
4.6. Western Blotting
Western blotting assays were performed as previously described [45] using the following
primary antibodies: anti-Notch2 (D76A6) XP #5732 (Cell Signaling, Danvers, MA, USA), anti-NICD2
SAB4502022 (Sigma-Aldrich, St. Louis, MI, USA), anti-Notch1 C-20 sc-6014 (Santa Cruz Biotechnology,
Dallas, TX, USA), anti-Sp1 (1C6) sc-420X (Santa Cruz Biotechnology), anti-cleaved PARP G7341
(Promega, Madison, WI, USA), anti-PARP #9542 (Cell Signaling), anti-GAPDH ab-8245 (Abcam,
Cambridge, UK) and anti-β-Actin (I-19) sc-1616 (Santa Cruz Biotechnology). Horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology) were used to detect immunoreactive
bands and binding was visualized by enhanced chemiluminescence (Perkin Elmer, Waltham, MA,
USA). ImageJ software was used to perform band densitometry. Protein levels are expressed as
relative to the internal control (β-Actin and Sp1). Nucleus/cytoplasmic fractionation was conducted
as previously described [46].
Int. J. Mol. Sci. 2017, 18, 2742 9 of 12
4.7. Immunofluorescence Studies
Immunofluorescence studies were conducted according to standard procedures, as described
elsewhere [47]. Briefly, KNS42 cells were plated on glass coverslips and fixed with 4%
paraformaldehyde (PFA) for 10 min at room temperature (RT). Fixed cultures were permeabilized
and blocked for 30 min with 5% donkey serum (DS) and 0.1% Triton X-100 (Sigma-Aldrich, St. Louis,
MI, USA) in phosphate buffered saline (PBS, Sigma-Aldrich, St. Louis, MI, USA). Cells were then
incubated overnight with anti-Notch2 antibody (#HPA048743, Sigma-Aldrich, St. Louis, MI, USA).
Secondary antibody conjugated with Alexa Fluor 594 (Thermo Fisher Scientific) was diluted 1:200 in
PBS with 5% DS and incubated with the specimens for 1 h at RT. Nuclei were counterstained with
Hoechst reagent. After washing, slides were mounted using anti-fade reagent (Dako Fluorescence
Mounting Medium, Carpinteria, CA, USA). Images were acquired using a FV1200 MPE laser scanning
confocal microscope (Olympus, Shinjuku, Tokyo, Japan) with a UPlanSAPO 20×/0.75 NA objective.
Imaris 8.1 software (Bitplane, Zürich, Switzerland) was used for image processing.
4.8. Plasmid Construction and Luciferase Reporter Assays
miR-29a-3p binding site in 3′-UTR gene regions was identified by bioinformatics analysis using
microRNA.org (http://www.microrna.org/microrna/home.do) [48,49]. Human Notch2 3′-UTR
(Figure S5) was amplified by polymerase chain reaction (PCR). A region of the human Notch2 3′-UTR
(Figure S5) containing the putative miR-29a-3p binding site was amplified by PCR using the primers:
Notch2 3′-UTR forward (5′-CACTCGAGAGTCCACCTCCAGTGTAG-3′) and Notch2 3′-UTR reverse
(5′-CAGCGGCCGCAGTCAATGGAATGCTTG-3′) and cloned into psiCheck-2-luciferase reporter
vector between the XhoI and NotI sites. 250 ng of the empty psiCheck2 vector or the recombinant
plasmid containing the human Notch2 3′-UTR were transiently co-transfected into KNS42 cells with
50 nM of miR-107, used as positive control, or miR-29a-3p or negative control microRNA using
Lipofectamine™ 2000 (Invitrogen, Thermo Scientific, Waltham, MA, USA). Twenty-four hours after
transfection, cells were harvested and subjected to the Firefly Luciferase Assay 2.0 (Biotium, Fremont,
CA, USA). Cells were incubated in 24-well plates for 15 min at room temperature with 100 µL of
1× Passive Lysis Buffer. Subsequently, 20 µL of the lysate was tested with 100 µL of firefly and Renilla
solution in a 96-well plate. Luciferase activity was detected with a luminometer (GLOMAX, Fitchburg,
WI, USA). Results are expressed as the ratio of Renilla to Firefly luciferase activity. Reported values are
means ± S.D. of values from at least three experiments, each performed in triplicate.
4.9. Statistical Analysis
Data reported in this paper are the means ± SD of at least three independent experiments each
performed in triplicate. Unpaired t-test, Paired t-test, one-way ANOVA and two-way ANOVA were
performed wherever appropriate using GraphPad Prism Software version 6.0 (GraphPad Prism,
La Jolla, CA, USA), p values <0.05 were considered to be statistically significant.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2742/s1.
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